Why this study matters for Usher syndrome
For people and families living with suspected Usher syndrome, reaching a clear diagnosis can take years. Usher syndrome can affect both vision and hearing, but its signs, timing, and severity vary widely between individuals. Retinal changes may overlap with other inherited retinal diseases, while specialized assessments—such as advanced retinal imaging, visual-field testing, and electrophysiology—may not always be immediately available.
A 2026 study published in Genes examined whether molecular testing early in the diagnostic process could help address this challenge. The researchers found that an ophthalmology-focused genetic panel provided a clinically actionable diagnosis in nearly 45% of people referred with suspected genetic eye diseases. Notably, Usher syndrome was the most common molecular diagnosis identified.
These findings support a practical idea with important implications for Usher syndrome: genetic testing does not need to be the final step after every other assessment has been completed. When a genetic eye disease is suspected, it may help guide the next steps from the beginning.
The study: testing early rather than waiting
The retrospective study included 101 consecutive patients evaluated at a tertiary referral center in northeastern Mexico between January 2020 and August 2023. All had signs or histories raising concern for a genetic eye disease.
Patients received comprehensive ophthalmic examinations. Testing such as optical coherence tomography (OCT), visual-field assessment, and fundus photography was used when clinically indicated. However, the researchers offered molecular testing early, including while patients waited for future testing, electrophysiology, or additional referral appointments.
The genetic test was a next-generation sequencing multigene panel designed for ophthalmic conditions. Rather than testing one gene at a time, this approach examines many genes associated with inherited eye diseases in a single analysis. This is particularly useful when different conditions can appear similar in the clinic or when a person’s symptoms do not yet fit neatly into one diagnostic category.
Key findings: Usher syndrome was the leading diagnosis
A clinically actionable molecular diagnosis was established in 45 of the 101 participants, producing an overall diagnostic yield of 44.6%. In other words, early panel testing identified a genetic explanation that could inform clinical care, counseling, or future planning for almost one in every two people in the study.
Across the group, researchers identified 165 genetic variants. These included 70 classified as pathogenic and 16 as likely pathogenic. The study also found 43 variants of uncertain significance—changes in DNA for which the available evidence was not sufficient to determine whether they cause disease—and 36 likely benign variants.
Among the 45 patients who received a molecular diagnosis, 10 had Usher syndrome, representing 22.2% of diagnosed cases. This made Usher syndrome the most frequent molecular diagnosis in the study.
Nine of these individuals had Usher syndrome type 2 associated with changes in USH2A, while one had Usher syndrome type 1B associated with MYO7A. These results underscore that Usher syndrome is genetically diverse: a clinical label alone is not the full diagnosis. Identifying the specific gene involved can provide a more precise foundation for understanding an individual’s condition.
Most diagnosed disorders in the study followed autosomal recessive inheritance, including many forms of Usher syndrome. In recessive conditions, disease generally occurs when a person inherits disease-causing changes in both copies of a relevant gene. A molecular diagnosis can therefore be valuable not only for the person tested, but also for family counseling and discussions about inheritance.
How an earlier genetic answer can shape care
The study does not suggest that careful eye examinations, hearing assessments, imaging, and functional testing are no longer needed. Instead, it proposes that genetic information can help make those evaluations more targeted.
For example, a result involving USH2A or MYO7A may focus future evaluation on features relevant to the corresponding form of Usher syndrome. It may also help clinicians distinguish Usher syndrome from other inherited retinal conditions with overlapping retinal findings. This can reduce uncertainty and help families move more efficiently toward appropriate multidisciplinary management.
Early genetic testing may be especially important in settings where advanced imaging or electrophysiological testing is difficult to access or delayed. The authors argue that an eye-disease-focused multigene panel can be an effective first-line strategy in such circumstances, helping to optimize limited clinical resources while patients await additional assessment.
Relevance for emerging treatments and research
The research landscape for inherited retinal diseases is increasingly gene-specific. As potential gene-based therapies continue to emerge, knowing the gene associated with a person’s condition becomes increasingly important for understanding research opportunities and possible eligibility for gene-specific therapeutic approaches.
This study does not evaluate a treatment for Usher syndrome, nor does it show that genetic testing itself changes vision or hearing outcomes. Its contribution is diagnostic: it demonstrates that early molecular testing can identify people with conditions such as USH2A- and MYO7A-associated Usher syndrome sooner in the care pathway.
A precise molecular diagnosis can also support more accurate prognosis discussions and direct attention to the clinical features that should be assessed over time.
Looking ahead
This study adds to the case for integrating genetic testing earlier into the evaluation of suspected inherited eye disease. For the Usher syndrome community, its central message is clear: when clinical findings raise the possibility of Usher syndrome, early testing of relevant genes may shorten the diagnostic journey and create a clearer path toward tailored evaluation, family counseling, and future gene-specific research.
As genetic testing becomes more integrated into eye care, studies like this can help define how molecular results and deep clinical phenotyping work best together—not as competing approaches, but as complementary tools for achieving a more timely and precise diagnosis.